Guida all'uso clinico dei biomarcatori in oncologia

premesse e generalità

Translated title of the contribution: Guidelines for clinical use of biomarkers in oncology: Premises and introductory concepts

Massimo Gion, Chiara Trevisiol, Silvia Pregno, Aline S C Fabricio

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In this document a working definition of circulating cancer biomarkers is provided and discussed within a broader definition of disease biomarkers and their possible classifications. The biomarker families possibly suitable for clinical use on the basis of available evidence are then considered, concluding that only few biomarkers may be helpful in the management of cancer patients. They are well known molecules discovered 20-30 yeas ago, quantitatively related to the tumour burden, encompassing classical "tumor markers" (CEA, AFP, hCG) and glycoproteins discovered by immunologic recognition (CA 125, CA 15.3, CA 19.9). The most relevant characteristics of quoted biomarkers are reported. The poor "cancer specificity" of available biomarkers is discussed, concluding that circulating concentrations of the socalled "tumor" markers are the sum of several variables including (if present) the malignancy. Non-tumor variables potentially responsible of variations in circulating concentrations of biomarkers are reported. They include physiological conditions and life style patterns, diseases other than cancer, and iatrogenic artefacts. The analytical and pre-analytical issues that may interfere with the biomarker determination, including autoantibodies, human antimouse monoclonal antibodies, and the "hook effect", are also examined.

Original languageItalian
Pages (from-to)97-106
Number of pages10
JournalBiochimica Clinica
Volume35
Issue number2
Publication statusPublished - Apr 2011

Fingerprint

Oncology
Biomarkers
Guidelines
Tumor Biomarkers
Neoplasms
Hooks
Tumor Burden
Autoantibodies
Artifacts
Life Style
Tumors
Glycoproteins
Monoclonal Antibodies
Molecules

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Medical Laboratory Technology

Cite this

Gion, M., Trevisiol, C., Pregno, S., & Fabricio, A. S. C. (2011). Guida all'uso clinico dei biomarcatori in oncologia: premesse e generalità. Biochimica Clinica, 35(2), 97-106.

Guida all'uso clinico dei biomarcatori in oncologia : premesse e generalità. / Gion, Massimo; Trevisiol, Chiara; Pregno, Silvia; Fabricio, Aline S C.

In: Biochimica Clinica, Vol. 35, No. 2, 04.2011, p. 97-106.

Research output: Contribution to journalArticle

Gion, M, Trevisiol, C, Pregno, S & Fabricio, ASC 2011, 'Guida all'uso clinico dei biomarcatori in oncologia: premesse e generalità', Biochimica Clinica, vol. 35, no. 2, pp. 97-106.
Gion M, Trevisiol C, Pregno S, Fabricio ASC. Guida all'uso clinico dei biomarcatori in oncologia: premesse e generalità. Biochimica Clinica. 2011 Apr;35(2):97-106.
Gion, Massimo ; Trevisiol, Chiara ; Pregno, Silvia ; Fabricio, Aline S C. / Guida all'uso clinico dei biomarcatori in oncologia : premesse e generalità. In: Biochimica Clinica. 2011 ; Vol. 35, No. 2. pp. 97-106.
@article{f2077c97a8b1441588e9f337f1cfefc6,
title = "Guida all'uso clinico dei biomarcatori in oncologia: premesse e generalit{\`a}",
abstract = "In this document a working definition of circulating cancer biomarkers is provided and discussed within a broader definition of disease biomarkers and their possible classifications. The biomarker families possibly suitable for clinical use on the basis of available evidence are then considered, concluding that only few biomarkers may be helpful in the management of cancer patients. They are well known molecules discovered 20-30 yeas ago, quantitatively related to the tumour burden, encompassing classical {"}tumor markers{"} (CEA, AFP, hCG) and glycoproteins discovered by immunologic recognition (CA 125, CA 15.3, CA 19.9). The most relevant characteristics of quoted biomarkers are reported. The poor {"}cancer specificity{"} of available biomarkers is discussed, concluding that circulating concentrations of the socalled {"}tumor{"} markers are the sum of several variables including (if present) the malignancy. Non-tumor variables potentially responsible of variations in circulating concentrations of biomarkers are reported. They include physiological conditions and life style patterns, diseases other than cancer, and iatrogenic artefacts. The analytical and pre-analytical issues that may interfere with the biomarker determination, including autoantibodies, human antimouse monoclonal antibodies, and the {"}hook effect{"}, are also examined.",
author = "Massimo Gion and Chiara Trevisiol and Silvia Pregno and Fabricio, {Aline S C}",
year = "2011",
month = "4",
language = "Italian",
volume = "35",
pages = "97--106",
journal = "Biochimica Clinica",
issn = "0393-0564",
publisher = "CLAS International",
number = "2",

}

TY - JOUR

T1 - Guida all'uso clinico dei biomarcatori in oncologia

T2 - premesse e generalità

AU - Gion, Massimo

AU - Trevisiol, Chiara

AU - Pregno, Silvia

AU - Fabricio, Aline S C

PY - 2011/4

Y1 - 2011/4

N2 - In this document a working definition of circulating cancer biomarkers is provided and discussed within a broader definition of disease biomarkers and their possible classifications. The biomarker families possibly suitable for clinical use on the basis of available evidence are then considered, concluding that only few biomarkers may be helpful in the management of cancer patients. They are well known molecules discovered 20-30 yeas ago, quantitatively related to the tumour burden, encompassing classical "tumor markers" (CEA, AFP, hCG) and glycoproteins discovered by immunologic recognition (CA 125, CA 15.3, CA 19.9). The most relevant characteristics of quoted biomarkers are reported. The poor "cancer specificity" of available biomarkers is discussed, concluding that circulating concentrations of the socalled "tumor" markers are the sum of several variables including (if present) the malignancy. Non-tumor variables potentially responsible of variations in circulating concentrations of biomarkers are reported. They include physiological conditions and life style patterns, diseases other than cancer, and iatrogenic artefacts. The analytical and pre-analytical issues that may interfere with the biomarker determination, including autoantibodies, human antimouse monoclonal antibodies, and the "hook effect", are also examined.

AB - In this document a working definition of circulating cancer biomarkers is provided and discussed within a broader definition of disease biomarkers and their possible classifications. The biomarker families possibly suitable for clinical use on the basis of available evidence are then considered, concluding that only few biomarkers may be helpful in the management of cancer patients. They are well known molecules discovered 20-30 yeas ago, quantitatively related to the tumour burden, encompassing classical "tumor markers" (CEA, AFP, hCG) and glycoproteins discovered by immunologic recognition (CA 125, CA 15.3, CA 19.9). The most relevant characteristics of quoted biomarkers are reported. The poor "cancer specificity" of available biomarkers is discussed, concluding that circulating concentrations of the socalled "tumor" markers are the sum of several variables including (if present) the malignancy. Non-tumor variables potentially responsible of variations in circulating concentrations of biomarkers are reported. They include physiological conditions and life style patterns, diseases other than cancer, and iatrogenic artefacts. The analytical and pre-analytical issues that may interfere with the biomarker determination, including autoantibodies, human antimouse monoclonal antibodies, and the "hook effect", are also examined.

UR - http://www.scopus.com/inward/record.url?scp=79954516587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954516587&partnerID=8YFLogxK

M3 - Articolo

VL - 35

SP - 97

EP - 106

JO - Biochimica Clinica

JF - Biochimica Clinica

SN - 0393-0564

IS - 2

ER -